ADCT Stock Summary and Trading Ideas (Adc Therapeutics SA Common Shares | NYSE:ADCT)

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.

As of October 14, 2024, ADCT stock price declined to $3.06 with 345,724 million shares trading.

ADCT has a beta of 2.37, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.06 to the broad based SPY ETF.

ADCT has a market cap of $295.74 million. This is considered a Small Cap stock.

Last quarter Adc Therapeutics SA Common Shares reported $17 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.19.

In the last 3 years, ADCT traded as high as $32.00 and as low as $.36.

The top ETF exchange traded funds that ADCT belongs to (by Net Assets): IWM, IWO, IWN, VTWO, IWC.

ADCT has outperformed the market in the last year with a return of +277.8%, while the SPY ETF gained +35.5%. However, in the most recent history, ADCT shares have underperformed the stock market with its stock returning -19.3% in the last 3 month period and -0.6% for the last 2 week period, while SPY has returned +5.3% and +2.2%, respectively.

ADCT support price is $2.92 and resistance is $3.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT shares will trade within this expected range on the day.